Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2

Transplantation

Volumn 68, Issue 2, 1999, Pages 288-293

  Onodera, Kazuhiko ^a,b   Chandraker, Anil ^a   Volk, Hans Dieter ^e   Ritter, Thomas ^e   Lehmann, Manfred ^c   Kato, Hirohisa ^d   Sayegh, Mohamed H ^a   Kupiec Weglinski, Jerzy W ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ALLOGRAFT; ANIMAL CELL; ARTICLE; CELL STIMULATION; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECIPIENT; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD4; ANTIGENS, DIFFERENTIATION; ARTERIOSCLEROSIS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNE TOLERANCE; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MALE; RATS; RATS, INBRED BN; RATS, INBRED LEW; RATS, INBRED WF; TH2 CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033609531     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199907270-00022     Document Type: Article

References (22)

1. Hancock WW, Di Stefano R, Braun P, Schweizer RT, Tilney NL, Kupiec-Weglinski JW. Cyclosporine and anti-interleukin 2 receptor mAb therapy suppress accelerated rejection of rat cardiac allografts through different effector mechanisms. Transplantation 1990; 49: 416.
2. + cells in the sensitization and effector phases of accelerated graft rejection. Transplantation 1991; 51: 226.
3. Wieder KJ, Hancock WW, Schmidbauer G, et al. Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-γ in rat recipients of cardiac allografts. J Immunol 1993; 151: 1158.
4. Schmidbauer G, Hancock WW, Wasowska B, Badger AM, Kupiec-Weglinski JW. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear/ endothelial cell activation, cytokine production, and cell adhesion. Transplantation 1994; 57: 933.
5. Heidecke CD, Hancock WW, Jakobs F, et al. α/β-T cell receptor-directed therapy in rat cardiac allograft recipients: treatment prior to alloantigen exposure prevents sensitization and abrogates accelerated rejection. Transplantation 1995; 59: 78.
6. Binder J, Lehmann M, Graser E, et al. The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. Transplantation 1996; 61: 804.
7. Onodera K, Lehmann M, Akalin E, Volk HD, Sayegh MH, Kupiec-Weglinski JW. Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in CD4 mAb-treated sensitized rat recipients. J Immunol 1996; 157: 1944.
8. Onodera K, Chandraker A, Schaub M, et al. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell mediated and humoral immune responses. J Immunol 1997; 159: 1711.
9. Lehmann M, Sternkopf F, Metz F, Volk HD. Induction of long-term survival of rat skin allografts by a novel, highly efficient anti-CD4 monoclonal antibody. Transplantation 1992; 54: 959.
10. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294.
11. Siegling A, Lehmann M, Platzer C, Emmrich F, Volk HD. A novel multispecific competitor fragment for quantitative PCR analysis of cytokine gene expression in rats. J Immunol Methods 1994; 177: 23.
12. Russell ME, Hancock WW, Akalin E, et al. Chronic cardiac rejection in the Lewis to F344 model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996; 97: 833.
13. Adams DH, Tilney NL, Collins JJ, Karnovsky MJ. Experimental graft arteriosclerosis. I. The Lewis-to-F344 allograft model. Transplantation 1992; 53: 1115.
14. Schaub M, Stadlbauer THW, Chandraker A, et al. Comparative strategies to induce long-term graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade: role of thymus and spleen. J Am Soc Nephrol 1998; 9: 891.
15. Qin S, Cobbold SP, Pope H, et al. "Infectious" transplantation tolerance. Science 1993; 259: 974.
16. Onodera K, Hancock WW, Graser E, et al. Type 2 helper T cell-type cytokines and the development of "infectious" tolerance in rat cardiac allograft recipients. J Immunol 1997; 158: 1572.
17. Onodera K, Volk HD, Ritter T, Kupiec-Weglinski JW. Thymus requirement and antigen dependency in the "infectious" tolerance pathway in transplant recipients. J Immunol 1998; 160: 5765.
18. Scully R, Quin S, Cobbold S, Waldmann H. Mechanisms in CD4 antibody-mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells. Eur J Immunol 1994; 24: 2383.
19. Goss JA, Flye MW, Lacy PE. Successful transfer of immune unresponsiveness to concordant rat islet xenografts. Transplantation 1996; 61: 9.
20. Nickerson P, Steiger J, Zheng XX, et al. Manipulation of cytokine networks in transplantation: false hope or realistic opportunity for tolerance? Transplantation 1997; 63: 489.
21. Snapper CV, Finkelman MFD, Paul WE. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236: 944.
22. Finkelman FD, Holmes J, Katona IM, et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990; 8: 303.